Skip to main content
. 2016 Apr 5;6(3):198–204. doi: 10.1016/j.apsb.2016.03.005

Figure 5.

Fig. 5

(A and B) The result of E17110 docking into the active site of the ligand-binding domain of LXRβ based on the X-ray co-crystal structure of T1317. (C) Activation of various LXRβ mutants by E17110, using the LXRβ-GAL4 chimera reporter assay. (D) E17110 (3 μmol/L) showed different LXRβ agonist activity on the wild-type group and different mutants in the LXRβ-GAL4 chimera reporter assays. Similar results were obtained in three independent experiments. Data are mean±SEM (n=3, *P<0.05 and **P<0.01 vs. control).